We are live on ! Find out more
RI

RTW Investments Portfolio holdings

AUM $10B
1-Year Est. Return 135.35%
This Fund
S&P 500
This Quarter Est. Return
+4.5%
1 Year Est. Return
+135.35%
3 Year Est. Return
+383.62%
5 Year Est. Return
+523.94%
10 Year Est. Return
+15,981.64%
AUM
$6.46B
AUM Growth
-$315M
Cap. Flow
+$85.5M
Cap. Flow %
1.32%
Top 10 Hldgs %
48.84%
Holding
76
New
7
Increased
23
Reduced
12
Closed
8

Top Buys

Rank Stock Value
1
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$362M
2
DYN icon
Dyne Therapeutics
DYN
+$95.8M
3
INSM icon
Insmed
INSM
+$68.8M
4
ISRG icon
Intuitive Surgical
ISRG
+$41.2M
5
GKOS icon
Glaukos
GKOS
+$34.8M

Top Sells

Rank Stock Value
1
RARE icon
Ultragenyx Pharmaceutical
RARE
+$163M
2
AVDL
Avadel Pharmaceuticals
AVDL
+$149M
3
SYK icon
Stryker
SYK
+$115M
4
SWAV
Shockwave Medical, Inc. Common Stock
SWAV
+$94M
5
TMO icon
Thermo Fisher Scientific
TMO
+$64.2M

Sector Composition

Rank Sector Weight
1 Healthcare 99.86%
2 Financials 0.14%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ISRG icon
26
Intuitive Surgical
ISRG
$132B
$90.1M 1.39%
202,456
+103,456
+105% +$41.2M
ARVN icon
27
Arvinas
ARVN
$560M
$79M 1.22%
2,967,897
-330,000
-10% -$10.5M
SYRE icon
28
Spyre Therapeutics
SYRE
$9.12B
$76.6M 1.19%
3,258,360
+1,025,600
+46% +$34.6M
CRGX
29
DELISTED
CARGO Therapeutics
CRGX
$67M 1.04%
4,078,122
+342,503
+9% +$6.51M
URGN icon
30
UroGen Pharma
URGN
$2.22B
$59.7M 0.92%
3,557,347
+300,000
+9% +$4.27M
SAGE
31
DELISTED
Sage Therapeutics
SAGE
$59.5M 0.92%
5,480,577
– –
ETNB
32
DELISTED
89bio
ETNB
$59.1M 0.92%
7,378,548
– –
STOK icon
33
Stoke Therapeutics
STOK
$2.06B
$57.1M 0.88%
4,224,838
– –
OBIO icon
34
Orchestra BioMed
OBIO
$249M
$45.8M 0.71%
5,620,640
– –
GKOS icon
35
Glaukos
GKOS
$10.1B
$45.7M 0.71%
386,291
+327,500
+557% +$34.8M
CGON icon
36
CG Oncology
CGON
$6.6B
$42.4M 0.66%
1,344,074
+930,404
+225% +$32.2M
TSHA icon
37
Taysha Gene Therapies
TSHA
$1.82B
$42.1M 0.65%
18,800,299
+207,114
+1% +$603K
NGNE icon
38
Neurogene
NGNE
$710M
$39M 0.6%
1,070,565
+301,443
+39% +$10.6M
GHRS icon
39
GH Research
GHRS
$2.1B
$38.8M 0.6%
3,327,129
– –
VCEL icon
40
Vericel Corp
VCEL
$2.29B
$36.8M 0.57%
801,397
-805,000
-50% -$38M
FULC icon
41
Fulcrum Therapeutics
FULC
$288M
$36.2M 0.56%
5,845,956
– –
CGEM icon
42
Cullinan Oncology
CGEM
$1.1B
$18.4M 0.28%
+1,052,630
New +$22.4M
DNTH icon
43
Dianthus Therapeutics
DNTH
$6.15B
$17.3M 0.27%
666,667
– –
ROIV icon
44
Roivant Sciences
ROIV
$25.4B
$15.4M 0.24%
1,454,273
– –
LENZ
45
LENZ Therapeutics
LENZ
$164M
$14.9M 0.23%
863,389
– –
TEM
46
Tempus AI
TEM
$8.32B
$14M 0.22%
+400,000
New +$12.3M
KYTX icon
47
Kyverna Therapeutics
KYTX
$471M
$13.9M 0.22%
1,852,711
– –
EPIX
48
DELISTED
ESSA Pharma
EPIX
$12.1M 0.19%
2,298,662
– –
REPL icon
49
Replimune Group
REPL
$1.08B
$10.2M 0.16%
+1,133,787
New +$7.9M
TXG icon
50
10x Genomics
TXG
$5.79B
$9.78M 0.15%
502,856
-1,052,000
-68% -$27.5M
1
2
3 4

Similar funds

HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
RA
Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return
GI
GAMCO Investors Greenwich, Connecticut $10.2B AUM 30.27% 1-Year Est. Return
IIM
INTECH Investment Management West Palm Beach, Florida $10.2B AUM 28.14% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
VPIM
Vanguard Personalized Indexing Management Oakland, California $10.2B AUM 34.45% 1-Year Est. Return
OIA
OneDigital Investment Advisors Overland Park, Kansas $10.2B AUM 16.58% 1-Year Est. Return
HI
HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

RTW Investments's Q2 2024 Portfolio in Review

As of Q2 2024, RTW Investments held 76 positions worth $6.46B, down 4.7% from $6.77B the previous quarter. Its ten largest holdings account for 49% of the portfolio.

RTW Investments's Q2 2024 filing shows 7 new, 23 increased, 12 reduced and 8 closed positions. Its largest new stake was Cullinan Oncology: 1,052,630 shares worth $18.4M. The largest sale was Ultragenyx Pharmaceutical, an estimated $163M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, down from 100% a quarter earlier, followed by Financials.

  • RTW Investments's largest Q2 2024 buy was Cullinan Oncology: 1,052,630 shares worth $18.4M.
  • RTW Investments added most to Madrigal Pharmaceuticals in Q2 2024, an estimated $362M increase.
  • RTW Investments's biggest Q2 2024 reduction was Ultragenyx Pharmaceutical, cutting an estimated $163M.
  • RTW Investments fully exited Avadel Pharmaceuticals in Q2 2024, selling an estimated $149M.
  • RTW Investments's ten largest holdings make up 49% of its $6.46B portfolio in Q2 2024.
  • RTW Investments opened 7 new positions and closed 8 in Q2 2024.
  • RTW Investments's portfolio value fell 4.7% quarter-over-quarter to $6.46B.

Based on RTW Investments's 13F filing for Q2 2024, filed 14 Aug 2024.